Can-Fite BioPharma Ltd. Proceeds from Debt, Net of Issuance Costs
Can-Fite BioPharma Ltd. (CANF) had Proceeds from Debt, Net of Issuance Costs of $4.47 million as of 2024-08-08, per its 6-K filed 2024-08-29.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromDebtNetOfIssuanceCosts · last filed 2024-08-29
- 2024-08-08: Proceeds from Debt, Net of Issuance Costs $4.47M.
| Period end | Proceeds from Debt, Net of Issuance Costs |
|---|---|
| 2024-08-08 | $4.47M 6-K · filed 2024-08-29 |